

June 24, 2019

Senator Thom Tillis  
113 Dirksen Senate Office Building  
Washington D.C., 20510

Senator Chris Coons  
218 Russell Senate Office Building  
Washington D.C., 20510

Representative Hank Johnson  
2240 Rayburn House Office Building  
Washington D.C., 20515

Representative Doug Collins  
1504 Longworth House Office Building  
Washington D.C., 20515

Representative Steve Stivers  
2234 Rayburn House Office Building  
Washington D.C., 20515

Dear Chairman Tillis, Ranking Member Coons, Chairman Johnson, Ranking Member Collins, and Representative Stivers:

We applaud your leadership in examining the current law on patent eligibility and strongly support legislation to reform Section 101 of the Patent Act. Such legislation is essential to future American innovation and security.

We believe that legislation to restore patent eligibility to its traditional role as a coarse filter that broadly encourages invention in all corners of science, engineering, medicine, and other disciplines is necessary. Unfortunately, recent judicially created loopholes now deny some of our best inventions, the patent protection they deserve and are in fact receiving in China, Europe, and elsewhere. These loopholes currently discourage inventors from pursuing research and development in areas that are critical not only to our future health and prosperity, but also to our security, as other nations invest to beat the United States in the race for the innovations of the future.

We enthusiastically endorse the goals of your proposed legislation to reform Section 101 to restore high quality, reliable patent protection to the United States. Your draft reforms to Section 101 would stimulate the private sector to invest in innovation, economic development, and job growth.

We also write to make clear in no uncertain terms that under your proposed legislation, naturally occurring materials and compositions as they exist in nature – including human genes – will remain patent ineligible, despite well-publicized claims to the contrary.

We look forward to continuing to work with each of you to reform Section 101 of the Patent Act to strengthen our patent system for the future prosperity and security of our nation.

Sincerely,

Aerin Medical  
Austin, TX

Alliance of U.S. Startups & Inventors for Jobs (USIJ)  
Washington, DC

American Business Defense Council  
Washington, DC

American Conservative Union  
Alexandria, VA

Biotechnology Innovation Organization (BIO)  
Washington, DC

Bristol-Myers Squibb  
New York, NY

California Life Sciences Association - CLSA  
San Diego, CA and South San Francisco, CA

Candesant Biomedical  
San Francisco, CA

Cardionomic, Inc.  
New Brighton, MN

Cleveland Medical Devices Inc.  
Cleveland, OH

Conservatives for Property Rights  
Washington, DC

Core Mobility Solutions  
San Jose, CA

Cummins Allison Corp.  
Mount Prospect, IL

CVRx  
Minneapolis, MN

Dolby Laboratories, Inc.  
San Francisco, CA

DOTS Technology Corp.  
Natick, MA

Earlens Corporation  
Menlo Park, CA

Enventys Partners  
Charlotte, NC

Exact Sciences Corp.  
Madison, WI

ExploraMed  
Mountain View, CA

Fallbrook Technologies  
Cedar Park, TX

Flocel Inc.  
Cleveland, OH

Foundry Therapeutics 1, Inc.  
Menlo Park, CA

Foundry Therapeutics 2, Inc.  
Menlo Park, CA

The Foundry, LLC  
Menlo Park, CA

Genentech, Inc.  
South San Francisco, CA

Great Lakes NeuroTechnologies Inc.  
Independence, OH

Half Moon Medical  
Menlo Park, CA

Innovation Alliance  
Washington, DC

Intact Vascular, Inc.  
Wayne, PA

InterDigital  
Wilmington, DE

Intrinsic Therapeutics  
Woburn, MA

Johnson & Johnson  
New Brunswick, NJ

JumpStart, Inc.  
Cleveland, OH

LamaMed Solutions  
Hayward, CA

Lauder Partners LLC  
Atherton, CA

Licensing Executives Society (U.S.A. and Canada), Inc.  
Alexandria, VA

Luma Therapeutics  
Millbrae, CA

Lungpacer Medical USA Inc.  
Exton, PA

The Market Institute  
Burke, VA

Medical Device Manufacturers Association (MDMA)  
Washington, DC

Hon. Paul Michel, Retired Federal Circuit Chief Judge  
Alexandria, VA

Minerva Surgical  
Redwood City, CA

Moximed  
Fremont, CA

NC8, Inc.  
Mountain View, CA

NeuroPace  
Mountain View, CA

NeuroWave Systems Inc.  
Cleveland Heights, OH

Novo Nordisk Inc.  
Plainsboro, NJ

Orbital Research Inc.  
Cleveland, OH

Pharmaceutical Research and Manufacturers of America (PhRMA)  
Washington, DC

Phyllis Schlafly Eagles  
St. Louis, MO

Procter & Gamble  
Cincinnati, OH

Relievent Medsystems, Inc.  
Minneapolis, MN

Retrophin, Inc.  
San Diego, CA

RPT Legal Strategies PC  
San Francisco, CA

Sandstone Diagnostics  
Pleasanton, CA

Sanibel Capital  
Zephyr Cove, NV

Senseonics, Inc.  
Germantown, MD

Setpoint Medical  
Valencia, CA

Small Business Technology Center  
Washington, DC

Solace Therapeutics, Inc.  
Framingham, MA

Solar Junction Corporation  
Tempe, AZ

SpyGlass Ophthalmics  
Mission Viejo, CA

TiVo Corporation  
San Jose, CA

U.S. Business & Industry Council  
Washington, DC

USG Corporation  
Chicago, IL

Velano Vascular, Inc.  
San Francisco, CA

Vytronus  
Sunnyvale, CA

Western Digital  
San Jose, CA

Wi-LAN Inc.  
Vista, CA

Willow  
Mountain View, CA

Xperi Corporation  
San Jose, CA